Morgan Stanley analyst Vikram Purohit maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $8.50.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vikram Purohit has given his Hold rating due to a combination of factors related to the recent acquisition offer for SAGE Therapeutics by Supernus Pharmaceuticals. The offer includes an upfront payment of $8.50 per share and a contingent value right (CVR) that could add up to $3.50 per share, depending on certain commercial milestones being met. This offer represents a significant premium over SAGE’s recent trading price and aligns closely with previous price targets.
Despite the attractive premium, Purohit’s Hold rating reflects uncertainties surrounding the realization of the CVR payments, which are contingent on achieving specific sales targets for Zurzuvae. Additionally, the likelihood of a competing bid is considered low due to the extensive strategic review process SAGE has undergone. These factors contribute to a cautious outlook, justifying the Hold recommendation as investors await further developments in the acquisition process.
In another report released yesterday, TD Cowen also maintained a Hold rating on the stock with a $8.50 price target.